Moberg Pharma AB (publ)

Stockholm Stock Exchange MOB.ST

Moberg Pharma AB (publ) Return on Capital Employed (ROCE) for the year ending December 31, 2023: -4.54%

Moberg Pharma AB (publ) Return on Capital Employed (ROCE) is -4.54% for the year ending December 31, 2023, a -25.67% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Moberg Pharma AB (publ) Return on Capital Employed (ROCE) for the year ending December 31, 2022 was -3.62%, a 20.22% change year over year.
Moberg Pharma AB (publ) Return on Capital Employed (ROCE) for the year ending December 31, 2021 was -4.53%, a -280.37% change year over year.
Moberg Pharma AB (publ) Return on Capital Employed (ROCE) for the year ending December 31, 2020 was 2.51%, a -67.28% change year over year.
Moberg Pharma AB (publ) Return on Capital Employed (ROCE) for the year ending December 31, 2018 was 7.68%, a 150.62% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

Stockholm Stock Exchange: MOB.ST

Moberg Pharma AB (publ)

CEO	Ms. Anna Ljung BA, M.Sc.
IPO Date	May 26, 2011
Location	Sweden
Headquarters	GustavslundsvAegen 42
Employees	10
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cleaning Supplies Clinical Trials Cosmetics Drugstores & Retail Pharmacies Personal Care Vaccines

Description

Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products in Europe, the United States, and internationally. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden.

Key trends

Past 5 years